The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 589.81% and ...

This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...

Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above ...

Bridgewater Associates slashed a stake in Apple, halved its Lilly investment, doubled down on Microsoft, and bought Moderna ...

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...

Company is investing $2.8bn in two Irish plants to produce its in-demand weight loss drugs and a new Alzheimer’s therapy ...